Literature DB >> 9765452

Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS.

S V Joag1, Z Q Liu, E B Stephens, M S Smith, A Kumar, Z Li, C Wang, D Sheffer, F Jia, L Foresman, I Adany, J Lifson, H M McClure, O Narayan.   

Abstract

The chimeric simian-human immunodeficiency virus SHIVKU-1, bearing the envelope of human immunodeficiency virus type 1 (HIV-1), causes fulminant infection with subtotal loss of CD4(+) T cells followed by development of AIDS in intravaginally inoculated macaques and thus provides a highly relevant model of sexually transmitted disease caused by HIV-1 in human beings. Previous studies using this SHIV model had shown that the vpu and nef genes were important in pathogenesis of the infection, and so we deleted portions of these genes to create two vaccines, DeltavpuDeltanefSHIV-4 (vaccine 1) and DeltavpuSHIVPPc (vaccine 2). Six adult macaques were immunized subcutaneously with vaccine 1, and six were immunized orally with vaccine 2. Both viruses caused infection in all inoculated animals, but whereas vaccine 1 virus caused only a nonproductive type of infection, vaccine 2 virus replicated productively but transiently for a 6- to 10-week period. Both groups were challenged 6 to 7 months later with pathogenic SHIVKU-1 by the intravaginal route. All four unvaccinated controls developed low CD4(+) T-cell counts (<200/microliter) and AIDS. The 12 vaccinated animals all became infected with SHIVKU-1, and two in group 1 developed a persistent productive infection followed by development of AIDS in one. The other 10 have maintained almost complete control over virus replication even though spliced viral RNA was detected in lymph nodes. This suppression of virus replication correlated with robust antiviral cell-mediated immune responses. This is the first demonstration of protection against virulent SHIV administered by the intravaginal route. This study supports the concept that sexually transmitted HIV disease can be prevented by parenteral or oral immunization.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765452      PMCID: PMC110324     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Authors:  S L Buge; E Richardson; S Alipanah; P Markham; S Cheng; N Kalyan; C J Miller; M Lubeck; S Udem; J Eldridge; M Robert-Guroff
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.

Authors:  L Musey; J Hughes; T Schacker; T Shea; L Corey; M J McElrath
Journal:  N Engl J Med       Date:  1997-10-30       Impact factor: 91.245

3.  Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.

Authors:  J Li; C I Lord; W Haseltine; N L Letvin; J Sodroski
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

4.  Functional epitope analysis of the human CD4 molecule. The MHC class II-dependent activation of resting T cells is inhibited by monoclonal antibodies to CD4 regardless whether or not they recognize epitopes involved in the binding of MHC class II or HIV gp120.

Authors:  M Merkenschlager; D Buck; P C Beverley; Q J Sattentau
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

5.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

6.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

7.  High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees.

Authors:  K Saksela; E Muchmore; M Girard; P Fultz; D Baltimore
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

8.  Antigenic variation of molecularly cloned SIVmac239 during persistent infection in a rhesus macaque.

Authors:  S V Joag; M G Anderson; J E Clements; M F McEntee; D P Sharma; R J Adams; O Narayan
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

9.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

10.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

View more
  13 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.

Authors:  P S Silverstein; G A Mackay; S Mukherjee; Z Li; M Piatak; J D Lifson; O Narayan; A Kumar
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration.

Authors:  Anil Kumar; Zhenqian Liu; Darlene Sheffer; Marilyn Smith; Dinesh K Singh; Shilpa Buch; Opendra Narayan
Journal:  Virology       Date:  2007-11-07       Impact factor: 3.616

4.  A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.

Authors:  Rama Rao Amara; Kalpana Patel; Genevieve Niedziela; Pragati Nigam; Sunita Sharma; Silvija I Staprans; David C Montefiori; Lakshmi Chenareddi; James G Herndon; Harriet L Robinson; Harold M McClure; Francis J Novembre
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Antigen expression kinetics and immune responses of mice immunized with noninfectious simian-human immunodeficiency virus DNA.

Authors:  Ramakrishna Hegde; ZhenQian Liu; Glenn Mackay; Marilyn Smith; Yahia Chebloune; Opendra Narayan; Dinesh K Singh
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

6.  Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Authors:  S L Buge; L Murty; K Arora; V S Kalyanaraman; P D Markham; E S Richardson; K Aldrich; L J Patterson; C J Miller; S M Cheng; M Robert-Guroff
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

7.  Longitudinal study to assess the safety and efficacy of a live-attenuated SHIV vaccine in long term immunized rhesus macaques.

Authors:  Thomas M Yankee; Darlene Sheffer; Zhengian Liu; Sukhbir Dhillon; Fenglan Jia; Yahia Chebloune; Edward B Stephens; Opendra Narayan
Journal:  Virology       Date:  2008-11-05       Impact factor: 3.616

Review 8.  Human immunodeficiency virus vaccine trials.

Authors:  Robert J O'Connell; Jerome H Kim; Lawrence Corey; Nelson L Michael
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

9.  Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239.

Authors:  Kristina Abel; Tracy Rourke; Ding Lu; Kristen Bost; Michael B McChesney; Christopher J Miller
Journal:  J Infect Dis       Date:  2004-09-24       Impact factor: 5.226

10.  Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail.

Authors:  Pramod N Nehete; Bharti P Nehete; Lori Hill; Pallavi R Manuri; Veerabhadran Baladandayuthapani; Lei Feng; Johnny Simmons; K Jagannadha Sastry
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.